Association of statin use with risk of dementia: A meta-analysis of prospective cohort studies

Geriatrics and Gerontology International

Volumn 13, Issue 4, 2013, Pages 817-824

  Song, Yu ^a   Nie, Hongwei ^b   Xu, Yong ^a   Zhang, Ling ^a   Wu, Yan ^a  

^a SOOCHOW UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

Author keywords

Cohort studies; Dementia; Intervention; Meta analysis; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

COHORT ANALYSIS; DEMENTIA; DRUG SAFETY; DRUG USE; FOLLOW UP; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION;

COHORT STUDIES; DEMENTIA; INTERVENTION; META-ANALYSIS; STATINS;

DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSPECTIVE STUDIES;

EID: 84885918484     PISSN: 14441586     EISSN: 14470594     Source Type: Journal    
DOI: 10.1111/ggi.12044     Document Type: Review

References (50)

1. Ilkin I, Ignat P. Dementia. Self Management of Chronic Disease 2009; 29-41.
2. Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S. Preventing Alzheimer disease and cognitive decline: evidence report/technology assessment, NO.193. Duke Evidence-based Practice Center 2007.
3. Peter VR, Nancy LM, Mary JL. The impact of dementia on the family. JAMA 1982; 248: 333-335.
4. Bernadette MG, Peter P. Can statins prevent or help treat Alzheimer's disease? J Alzheimers Dis Other Demen 2010; 20: 925-933.
5. Notkola IL, Sulkava R, Pekkanen J etal. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology 1998; 17: 14-20.
6. Evans RM, Emsley CL, Gao S etal. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000; 54: 240-242.
7. Hall K, Murrell J, Ogunniyi A etal. Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba. Neurology 2006; 66: 223-227.
8. Jick H, Zornberg GL, Jick S, Sesharia S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
9. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or Alzheimer's disease by statins: a meta-analysis. Dement Geriatr Cogn Disord 2007; 23: 194-201.
10. Stroup DF, Berlin JA, Morton SC etal. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327 (7414): 557-560.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
14. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315 (7109): 629-634.
15. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Geriatr Med 2008; 6 (8): CD007514.
16. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol Ser A Biol Sci Med Sci 2002; 57: M414-M418.
17. Carl JV. Prevention of stroke and dementia with statins: effects beyond lipid lowering. Am J Cardiol 2003; 91 (Suppl): 23B-29B.
18. Li G, Higdon R, Kukull WA etal. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63: 1624-1628.
19. Peter PZ, Larry D, Khachaturian AS etal. Do statins Reduce Risk of Incident Dementia and Alzheimer Disease? Arch Gen Psychiatry 2005; 62: 217-224.
20. Thomas DR, John CB, Bruce MP etal. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005; 62: 1047-1051.
21. Li G, Larson EB, Sonnen JA etal. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 2007; 69: 878-885.
22. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71: 344-350.
23. Haag M, Hofman A, Koudstaal PJ, Stricker C, Breteler B. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. J Neurol Neurosurg Psychiatry 2009; 80: 13-17.
24. Smeeth L, Douglas I, Hall AJ, Hubbardd R, Evans S. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009; 67: 99-109.
25. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
26. Shepherd J, Cobbe SM, Ford I etal. for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-1307.
27. Sacks FM, Pfeffer MA, Moye LA etal. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
28. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-1357.
29. Downs JR, Clearfield M, Weis S etal. for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-1622.
30. Robins SJ, Despres JP. MRC/BHF Heart Protection Study. Lancet; 360 (9374): 1780.
31. Nash DT, Fillit H. Cardiovascular disease risk factors and cognitive impairment. Am J Cardiol 2006; 97: 1262-1265.
32. Luchsinger JA, Reitz C, Honig LS etal. Aggregation of vascular risk factors and risk of incident Alzheimer disease. Neurology 2005; 65: 545-551.
33. Newman AB, Fitzpatrick AL, Lopez O etal. Dementia and Alzheimer's disease incidence in relationship to cardiovascular disease in the Cardiovascular Health Study cohort. J Am Geriatr Soc 2005; 53: 1101-1107.
34. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994; 308 (6944): 1604-1608.
35. Szwast SJ, Hendrie HC, Lane KA etal. Association of statin use with cognitive decline in elderly African Americans. Neurology 2007; 69: 1873-1880.
36. Vega GL, Weiner MF, Lipton AM etal. Reduction in levels of 24S-hydroxycholesterol by statin treatment inpatients with Alzheimer disease. Arch Neurol 2003; 60: 510-515.
37. Simons M, Schwarzler F, Lutjohann D etal. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann Neurol 2002; 52: 346-350.
38. Dufouil C, Richard F, Fievet N etal. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005; 64: 1531-1538.
39. Green RC, McNagny SE, Jayakumar P etal. Statin use and the risk of Alzheimer's disease: the MIRAGE Study. Alzheimers Dement 2006; 2: 96-103.
40. Rockwood K, Kirkland S, Hogan DB etal. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223-227.
41. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors [see comment]. Arch Neurol 2000; 57: 1439-1443.
42. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23: 94-98.
43. Bernick C, Katz R, Smith NL etal. Statins and cognitive function in the elderly. The Cardiovascular Health Study. Neurology 2005; 65: 1388-1394.
44. Sparks DL, Sabbagh MN, Connor DJ etal. Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 2005; 62: 753-757.
45. Robert C, Green SE. Statin use and the risk of Alzheimer's disease: the MIRAGE Study. Alzheimers Dement 2006; 2: 96-103.
46. Sparks L. Statins and cognitive function. J Neurol Neurosurg Psychiatry 2009; 80: 1-2.
47. Weih M, Degirmenci Ü, Kreil S, Kornhuber J. Physical activity and Alzheimer's disease: a meta-analysis of cohort studies. Gero Psych 2010; 23: 17-20.
48. MRC/BHF Heat Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
49. Shepherd J, Blauw GJ, Murphy MB etal. Pravastatin in Elderly Individuals at Risk of Vascular Disease(PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-1630.
50. Alba R, Jordi P, Marta A. Cholesterol lowering and beyond: role of statin in Alzheimer's Disease. Aging Health 2008; 4: 171-180.